Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CMND
CMND logo

CMND Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
2.698
Open
2.300
VWAP
2.52
Vol
332.69K
Mkt Cap
2.64M
Low
2.280
Amount
839.27K
EV/EBITDA(TTM)
--
Total Shares
1.02M
EV
-8.04M
EV/OCF(TTM)
--
P/S(TTM)
--
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.
Show More

Events Timeline

(ET)
2026-05-26
08:40:00
Clearmind Medicine Receives Approval from Johns Hopkins for CMND-100 Clinical Trial
select
2026-05-21 (ET)
2026-05-21
11:30:00
Enveric Biosciences Reports Q1 Earnings with Cash Balance of Approximately $10.3M
select
2026-05-18 (ET)
2026-05-18
09:00:00
Clearmind Signs Research Agreement with Hebrew University
select
2026-05-14 (ET)
2026-05-14
11:20:00
GH Research Reports Q1 Loss of 26 Cents, Cash at $267.3M
select
2026-05-05 (ET)
2026-05-05
09:00:00
Clearmind Medicine Files European Patent Application
select
2026-04-30 (ET)
2026-04-30
16:41:00
Clearmind Medicine Files to Sell 22.63M Common Shares
select

News

NASDAQ.COM
2.0
09:04 AMNASDAQ.COM
Multiple Companies See Significant Stock Price Gains
  • CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw its stock price jump nearly 80% to $9.11 on Tuesday as it advances the development of its Ebola PCR assay, which is expected to significantly enhance the company's competitiveness in the molecular diagnostics market.
  • NRXP Regulatory Catalysts: NRx Pharmaceuticals Inc. (NRXP) shares rose over 30% to $4.31, driven by the anticipation of a New Drug Application submission to the FDA, which is expected to boost the company's market share in the treatment of suicidal depression.
  • ECOR Revenue Growth: electroCore Inc. (ECOR) reported a 43% revenue increase in Q1, with expectations of a 30% rise in annual revenue compared to 2025, leading to a 33.58% stock price increase, indicating strong performance in the bioelectronic medicine sector.
  • OTLK Regulatory Progress: Outlook Therapeutics Inc. (OTLK) shares jumped over 29% to $0.40 following positive regulatory developments regarding LYTENAVA, with plans to resubmit the Biologics License Application in June 2026, reflecting a strategic shift in their approach to FDA engagement.
Newsfilter
9.0
05-26Newsfilter
Clearmind Medicine Receives Approval for Phase I/II Clinical Trial
  • Clinical Trial Approval: Clearmind Medicine Inc. announced that its CMND-100 Phase I/II clinical trial has received approval from the Johns Hopkins Medicine Institutional Review Board, marking a significant advancement in the company's efforts to address alcohol use disorder and is expected to facilitate the smooth progression of subsequent research.
  • Research Phase Progress: This approval allows the company to proceed with Parts B and C of the trial, reflecting the solid foundation laid by Clearmind's earlier successes at one of the world's leading clinical research institutions, which is crucial for future studies.
  • CEO Commentary: CEO Dr. Adi Zuloff-Shani stated that this IRB approval represents an important step in the company's clinical development program, demonstrating confidence in the potential of its non-hallucinogenic MEAI-based candidate for patients suffering from alcohol use disorder, thereby enhancing market expectations for its products.
  • Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to seek additional patents in the future to strengthen its competitive position in the neuroplastogen drug sector and ensure the market standing of its innovative therapeutics.
seekingalpha
8.5
05-19seekingalpha
Clearmind Medicine to Execute 1-for-10 Reverse Stock Split
  • Reverse Stock Split Plan: Clearmind Medicine has announced a 1-for-10 reverse stock split effective May 21, 2026, aimed at regaining compliance with the Nasdaq Minimum Bid Price Rule, which will reduce the number of issued and outstanding common shares from 10,190,337 to approximately 1,019,033, thereby increasing the share price to meet compliance requirements.
  • Market Reaction: Following the reverse split announcement, Clearmind's shares fell by 20% in premarket trading, indicating market concerns about the company's future prospects, which could undermine investor confidence and exacerbate liquidity risks.
  • Compliance Pressure: This reverse stock split is a response to Nasdaq compliance pressures, as failure to restore the share price within the stipulated time frame could lead to delisting risks, posing significant challenges to the company's long-term development.
  • Strategic Implications: By implementing the reverse stock split, Clearmind aims to attract more institutional investors by increasing its share price, thereby enhancing market recognition and creating conditions for future financing, although short-term price volatility may increase.
Newsfilter
8.5
05-19Newsfilter
Clearmind Announces 1-for-10 Reverse Stock Split
  • Reverse Stock Split: Clearmind Medicine Inc. announced a 1-for-10 reverse stock split effective May 21, 2026, aimed at regaining compliance with Nasdaq's Minimum Bid Price Rule, which will reduce the number of outstanding shares from 10,190,337 to approximately 1,019,033, thereby potentially increasing the share price to meet listing requirements.
  • Board Approval: The reverse split was approved by the company's board on March 18, 2026, reflecting proactive measures taken in response to stock price pressures, aimed at boosting investor confidence and maintaining its position in the capital markets.
  • No Fractional Shares: Following the reverse split, no fractional shares will be issued, with all fractions rounded up to the nearest whole share, simplifying the shareholder structure and reducing potential shareholder confusion.
  • Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to seek additional patents in the future to enhance its market competitiveness in the non-hallucinogenic drug sector, demonstrating the company's commitment to innovation and intellectual property.
Newsfilter
8.5
05-15Newsfilter
Clearmind Medicine Engages in Federal Policy Summit
  • Summit Participation: Clearmind Medicine's CEO, Dr. Adi Zuloff-Shani, was appointed as a delegate to the 2026 Federal Policy Summit held on May 14 in Washington, D.C., aimed at fostering dialogue between the biopharma industry and policymakers to advance the responsible development of psychedelic therapies.
  • Clinical Trial Progress: Clearmind is advancing its non-hallucinogenic psychedelic candidate, currently undergoing Phase IIa clinical trials at leading institutions like Johns Hopkins and Yale, which not only showcases the company's commitment to innovative drug development but also addresses significant unmet health needs.
  • Intellectual Property Strategy: Clearmind holds 19 patent families and 31 granted patents, with plans to seek additional patents as warranted, indicating a proactive approach to intellectual property that aims to enhance its market competitiveness and technological barriers.
  • Industry Collaboration and Impact: The summit brought together key figures from the U.S. Congress and global biopharma CEOs, emphasizing the importance of cross-sector collaboration, and Clearmind's participation may pave the way for future policy support and market access.
Newsfilter
9.0
04-27Newsfilter
Clearmind's Positive Clinical Trial Results May Support Breakthrough Therapy Designation
  • Clinical Trial Progress: Clearmind Medicine is evaluating its candidate CMND-100 for eligibility for the FDA's Breakthrough Therapy Designation based on positive results from its ongoing Phase I/IIa clinical trial for Alcohol Use Disorder, indicating significant therapeutic potential that could open new market opportunities for the company.
  • Policy Support: The recent Executive Order signed by President Trump accelerates FDA review processes for certain breakthrough therapies, providing favorable conditions for CMND-100's application and further enhancing Clearmind's strategic position in the competitive biotech market.
  • Market Demand: Alcohol Use Disorder represents a serious health issue affecting millions globally with limited treatment options, and the successful development of CMND-100 could address this substantial unmet medical need, potentially yielding significant economic benefits for the company.
  • Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to continue expanding its intellectual property portfolio to support drug development and commercialization strategies, ensuring a competitive edge in future market dynamics.

Valuation Metrics

The current forward P/E ratio for Clearmind Medicine Inc (CMND.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Clearmind Medicine Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what stocks are falling today
Intellectia · 2580 candidates
Price Change Pct: <= $0.00
Ticker
Name
Market Cap$
top bottom
BTM logo
BTM
Bitcoin Depot Inc
32.61M
LICN logo
LICN
Lichen International Ltd
137.90M
GOSS logo
GOSS
Gossamer Bio Inc
79.80M
WOK logo
WOK
WORK Medical Technology Group Ltd
11.49M
YOOV logo
YOOV
Concorde International Group Ltd
290.54M
NEOV logo
NEOV
NeoVolta Inc
109.34M
sort by price
Intellectia · 16 candidates
Region: USPrice: $0.20 - $5.00Volume: >= 1,000,000Price Change Pct: >= $10.00List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
OTLK logo
OTLK
Outlook Therapeutics Inc
32.35M
TOVX logo
TOVX
Theriva Biologics Inc
11.80M
CANG logo
CANG
Cango Inc
198.55M
SILO logo
SILO
Silo Pharma Inc
8.38M
BLNK logo
BLNK
Blink Charging Co
99.60M
CUE logo
CUE
Cue Biopharma Inc
59.20M
cheapest top moving penny stocks
Intellectia · 16 candidates
Region: USPrice: $0.20 - $5.00Volume: >= 1,000,000Price Change Pct: >= $10.00List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
ENVB logo
ENVB
Enveric Biosciences Inc
4.44M
TOVX logo
TOVX
Theriva Biologics Inc
11.80M
CMND logo
CMND
Clearmind Medicine Inc
2.00M
CUE logo
CUE
Cue Biopharma Inc
59.20M
CANG logo
CANG
Cango Inc
198.55M
TCRX logo
TCRX
TScan Therapeutics Inc
67.71M
stocks under $5 likely to be bullish today
Intellectia · 30 candidates
Price: $0.50 - $5.00Rsi Category: moderatePrice Change Pct: >= $2.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $5.00
Ticker
Name
Market Cap$
top bottom
JCSE logo
JCSE
JE Cleantech Holdings Ltd
5.26M
SLND logo
SLND
Southland Holdings Inc
66.02M
IONR logo
IONR
ioneer Ltd
275.18M
RZLV logo
RZLV
Rezolve AI PLC
949.87M
BZUN logo
BZUN
Baozun Inc
121.73M
SKIL logo
SKIL
Skillsoft Corp
34.60M
Low float stock screener
Intellectia · 1484 candidates
List Exchange: XNYS, XNAS, XASEFloating Shares: <= 20,000,000
Ticker
Name
Market Cap$
top bottom
LGHL logo
LGHL
Lion Group Holding Ltd
638.91K
LRHC logo
LRHC
La Rosa Holdings
711.55K
RAYA logo
RAYA
Erayak Power Solution Group Inc
831.04K
NIVF logo
NIVF
NewGenIvf Group Ltd
864.77K
QH logo
QH
Quhuo Ltd
948.08K
BDRX logo
BDRX
Biodexa Pharmaceuticals PLC
1.01M
Find stocks with low float
Intellectia · 2888 candidates
Region: USShares Outstanding: <= 150,000,000
Ticker
Name
Market Cap$
top bottom
ADTX logo
ADTX
Aditxt Inc
2.59M
GWAV logo
GWAV
Greenwave Technology Solutions Inc
4.33M
GDHG logo
GDHG
Golden Heaven Group Holdings Ltd
5.19M
AREB logo
AREB
American Rebel Holdings Inc
3.47M
IPW logo
IPW
iPower Inc
5.62M
WTO logo
WTO
UTime Ltd
1.44M

Whales Holding CMND

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Clearmind Medicine Inc (CMND) stock price today?

The current price of CMND is 2.59 USD — it has increased 14.6

What is Clearmind Medicine Inc (CMND)'s business?

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.

What is the price predicton of CMND Stock?

Wall Street analysts forecast CMND stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMND is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Clearmind Medicine Inc (CMND)'s revenue for the last quarter?

Clearmind Medicine Inc revenue for the last quarter amounts to -3.66M USD, increased 144.62

What is Clearmind Medicine Inc (CMND)'s earnings per share (EPS) for the last quarter?

Clearmind Medicine Inc. EPS for the last quarter amounts to -2084949.00 USD, increased 64.76

How many employees does Clearmind Medicine Inc (CMND). have?

Clearmind Medicine Inc (CMND) has 4 emplpoyees as of May 27 2026.

What is Clearmind Medicine Inc (CMND) market cap?

Today CMND has the market capitalization of 2.64M USD.